EGFR Clinical Trials in Guangzhou, Guangdong
10 recruitingGuangzhou, Guangdong, China
Showing 1–10 of 10 trials
Recruiting
Not Applicable
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
Leptomeningeal MetastasisNSCLC (Advanced Non-small Cell Lung Cancer)EGFR Activating Mutation+1 more
Guangzhou University of Traditional Chinese Medicine42 enrolled1 locationNCT07348965
Recruiting
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
EGFR Mutant Advanced Non-small Cell Lung CancerCentral Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd.800 enrolled34 locationsNCT07143045
Recruiting
Phase 2
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
NSCLCEGFRAdjuvant Drug Therapy
Betta Pharmaceuticals Co., Ltd.28 enrolled2 locationsNCT07181499
Recruiting
Phase 1Phase 2
A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Wayshine Biopharm, Inc.100 enrolled12 locationsNCT06631989
Recruiting
Phase 1Phase 2
A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations
EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor
Sun Yat-sen University71 enrolled1 locationNCT06947811
Recruiting
Phase 2
Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study
Non-small Cell Lung Cancer (NSCLC)Leptomeningeal MetastasesBrain Metastases+2 more
Li-kun Chen70 enrolled1 locationNCT06728865
Recruiting
Phase 2
Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer
Non-small Cell Lung CancerEGFR Exon 20 Insertion Mutation
BeBetter Med Inc200 enrolled2 locationsNCT06706713
Recruiting
Phase 2
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
Non-small Cell Lung Cancer MetastaticEGFR G719XEGFR L861Q+1 more
Sun Yat-sen University23 enrolled1 locationNCT06517953
Recruiting
Early Phase 1
EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer
EGFR/ B7H3-positive Advanced Lung CancerEGFR/ B7H3-positive Advanced Triple-negative Breast Cancer
Second Affiliated Hospital of Guangzhou Medical University30 enrolled1 locationNCT05341492
Recruiting
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
Non-small Cell Lung Cancer (NSCLC)EGFR-TKI Resistant MutationEGFR-TKI Sensitizing Mutation+2 more
Sun Yat-sen University1,000 enrolled1 locationNCT01994057